DEVELOPMENT OF THE EMULGE LFOR THE ANDROGENIC ALOPECIA TREATMENT

EUREKA Health Sciences ◽

10.21303/2504-5679.2020.001427 ◽

2020 ◽

Vol 5 ◽

pp. 82-91

Author(s):

Inna Yarema ◽

Marianа Fedorovska ◽

Natalia Polovko

Keyword(s):

Hair Loss ◽

Mechanical Stability ◽

Later Life ◽

Acid Value ◽

Potassium Sorbate ◽

Androgenic Alopecia ◽

Sophora Japonica ◽

Female Pattern Hair Loss ◽

Semi Solid ◽

Biopharmaceutical Properties

Androgenic alopecia (AGA) is the most common alopecia that is heritable, androgen-dependent and occurs in both sexes with defined patterns such as Male pattern hair loss in men and Female pattern hair loss in women. AGA affects at least 50 % of men by the age of 50 years, and up to 70 % of all males in later life. The aim.The research was aimed to substantiate the optimal concentration of excipients and active pharmaceutical ingredients (APIs) of the emulgel intended for the topical treatment of androgenic alopecia. Materials and methods. In this study the samples of the emulgel bases containing different carbomer Ultrez10 concentrationsin the range of 0.3–0.6 % and its neutralizers (0.1 % of potassium sorbate and 0 % or 0.2 % of triethanolamine) were used. Colloidal and thermal stability, pH, rheological properties (structural viscosity, mechanical stability, degree of thixotropy) of these samples were determined. The emulgel samples with different percentages of the Serenoa repens dry extract and the Sophora japonica tincture were used in the biopharmaceutical studies. The samples of the emulgel with the antioxidant butylhydroxytoluene different concentrations (0 %, 0.01 %, 0.02 %, 0.03 %) were used to determine acid value during 1 year of the emulgel storage. Results and discussion. It was experimentally substantiated the optimal ratio of the emulgel ingredients that provide good APIs release and necessary consumer properties of the semi-solid remedy like application compliance, safety and storage stability. Conclusions. Physicochemical, rheological and biopharmaceutical properties of emulgel bases have been studied. It was found that the base №2 (in which the concentrations of Carbomer Ultraz 10, potassium sorbate and triethanolamine are 0.3 %, 0.1 %, 0.2 % respectively) possessed the optimal properties. Considering the results of the complete range of experimental research it was developed the final formulation of the emulgel intended for AGA treatment which included the concentration of the APIs, neutralizers, preservatives, antioxidant and fragrance.

Get full-text (via PubEx)

Hair loss: a clinical update

Journal of Aesthetic Nursing ◽

10.12968/joan.2019.8.9.422 ◽

2019 ◽

Vol 8 (9) ◽

pp. 422-429

Author(s):

Lucy Millar-Hume ◽

Farah Ali

Keyword(s):

Hair Loss ◽

Androgenic Alopecia ◽

Levels Of Evidence ◽

Female Pattern Hair Loss ◽

Male Pattern

Hair loss is classified into non-scarring and scarring alopecias, the latter being further subdivided into primary and secondary forms. These classifications are also referred to as non-cicatricial and cicatricial hair loss. This article focuses on androgenic alopecia (AGA) and will, at times, be referred to as male pattern hair loss (MPHL) or female pattern hair loss (FPHL). Essentially, AGA is a non-scarring, benign form of alopecia, generally related to ageing and where, on the whole, a proportion of hair can grow back. Aestheticians should be prepared to answer a patient's questions and concerns and be familiar with the current levels of evidence surrounding the myriad of treatments available.

Get full-text (via PubEx)

Is Every Patient of Hair Loss a Candidate for Hair Transplant?—Deciding Surgical Candidacy in Pattern Hair Loss

Indian Journal of Plastic Surgery ◽

10.1055/s-0041-1739247 ◽

2021 ◽

Author(s):

Robert H. True

Keyword(s):

Hair Loss ◽

Body Dysmorphic Disorder ◽

Young Patients ◽

Androgenic Alopecia ◽

Hair Transplantation ◽

Detailed History ◽

Hair Transplant ◽

Female Pattern Hair Loss ◽

Unrealistic Expectations ◽

Male Pattern

AbstractPatterned hair loss which includes both male pattern hair loss (MPHL) or androgenic alopecia (AGA) and female pattern hair loss (FPHL) is the most common indication for hair transplant surgery. However, not all such patients are candidates for hair transplants. There are eight conditions that cause patients to not be appropriate candidates. These are: diffuse unpatterned alopecia (DUPA), cicatricial alopecia (CA), patients with unstable hair loss, patients with insufficient hair loss, very young patients, patients with unrealistic expectations, patients with psychologic disorders such as body dysmorphic disorder (BDD) and trichotillomania, and patients who are medically unfit. In addition, there are patients who are poor candidates and who should undergo hair transplantation only if they understand and accept limited results. The key to identifying these patients involves performing careful and detailed history and examination at the time of consultation.

Get full-text (via PubEx)

Comparative study between the efficacy of topical sildenafil and topical minoxidil in the treatment of male androgenic alopecia

QJM ◽

10.1093/qjmed/hcab093.007 ◽

2021 ◽

Vol 114 (Supplement_1) ◽

Author(s):

Ali Abdulkareem Al-Shabkhon ◽

Adel Ahmed Halim Emam ◽

Ahmed Abd Elfattah Afify

Keyword(s):

Hair Loss ◽

Treated Group ◽

Treatment Modalities ◽

Androgenic Alopecia ◽

Men And Women ◽

Female Pattern Hair Loss ◽

Topical Minoxidil ◽

Temporal Side ◽

Male Patients ◽

Incidence Increase

Abstract Background Androgenic alopecia is the most common form of alopecia in men and women. Its incidence increase with age, many treatment modalities are available but results are variable. Androgenetic alopecia is a hereditary thinning of the hair induced by androgens in genetically susceptible men and women. Also known as male-pattern hair loss or common baldness in men and female-pattern hair loss in women. Thinning of hair usually begins between 12 and 40 years old in males and females. Inheritance is polygenic. Aim of the study To evaluate and compare the efficacy, safety and side effects of topical sildenafil and topical minoxidil in the treatment of androgenic alopecia Patients and methods This exploratory pilot study included 30 male patients suffering from androgenic alopecia. Included patients were divided into 2 equal groups based on treatment received; one group received 1% topical sildenafil and the other group received 55 topical minoxidil. Assessment of treatment response was done using trichoscopy. Results Sildenafil treated group showed statistically significant increase in VH and TH count at 18 cm point, 24 cm point after treatment compared to before treatment. While, temporal side showed statistically significant increase in VH only. minoxidil treated group showed statistically significant increase in TH count, T/V hair ratio and hair thickness at 18 cm point and temporal side after treatment compared to before treatment. VH count was significantly decreased after treatment compared to before treatment at 18 cm point. At 24 cm point, only TH was significantly increased after treatment compared to before treatment.

Get full-text (via PubEx)